fbpx

molecules of the month

ZN-c3

selective oral Wee1 kinase inh. (300 mg QD)

Ph. II candidate for uterine serous carcinoma

from literature starting point

Journal of Medicinal Chemistry

Zentalis Pharmaceuticals, San Diego, CA, USA

ZN-c3
1 min read

The Zentalis Wee1 inhibitor, ZN-c3, is a highly selective kinase inhibitor that is currently being evaluated in Ph. II clinical trials in adult women with recurrent or persistent uterine serous carcinoma (USC). The starting pyrazolopyrimidinone series was from the WO2013126656 patent, and while the molecule is similar to other kinase inhibitors (e.g. adavosertib, AZD1775), the ethyl group of the tertiary alcohol provided an unexpected improvement of potency while allowing maintenance of other properties including intrinsic clearance. It is an interesting example of navigating tight IP space to find a development candidate.


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: